CJC-1295: Growth Hormone Releasing Hormone Analog

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), the hypothalamic peptide that triggers pituitary GH release. Two distinct forms exist: CJC-1295 without DAC (also called Modified GRF 1-29) and CJC-1295 with DAC. The Drug Affinity Complex (DAC) modification fundamentally changes the pharmacokinetics by enabling albumin binding that extends half-life from approximately 30 minutes to over 7 days. Understanding this distinction is essential for interpreting the literature and selecting appropriate protocols.

GHRH Physiology and CJC-1295 Mechanism

The hypothalamic-pituitary GH axis operates through a push-pull dynamic. GHRH, secreted by the hypothalamus, binds GHRH receptors on somatotroph cells in the anterior pituitary, triggering GH synthesis and secretion. Somatostatin, the opposing peptide, inhibits GH release. GH itself feeds back to suppress GHRH and stimulate somatostatin, creating the pulsatile pattern of GH secretion characteristic of physiological function.

Natural GHRH (44 amino acids) has a very short half-life — minutes — due to rapid proteolytic degradation. The 1-29 fragment (GRF 1-29) retains full biological activity but is similarly short-lived. CJC-1295 is a modified version of GRF 1-29 with four amino acid substitutions that resist proteolytic degradation, extending the half-life to approximately 30 minutes without DAC.

The DAC modification adds a lysine residue with an NHS-ester group that enables covalent binding to serum albumin. Albumin has a circulating half-life of approximately 19 days, and CJC-1295 bound to albumin shares this extended residence time. This creates a continuous GHRH signal lasting over a week per injection rather than the pulse-and-fade of the unmodified peptide.

Pulsatile vs. Continuous GH Stimulation

The critical clinical question is whether continuous GH stimulation (DAC version) or pulsatile stimulation (non-DAC version) is preferable for the intended goals.

Physiological GH secretion is highly pulsatile — large nocturnal pulses separated by periods of low baseline secretion. This pulsatility is not incidental; it is required for optimal GH receptor sensitivity and downstream IGF-1 production. Continuous GH stimulation leads to GH receptor desensitization, potentially blunting the effect over time.

CJC-1295 without DAC, when dosed 2-3 times daily subcutaneously, creates pseudo-pulsatile GH secretion that better mimics physiological patterns. The GHRH signal is present during the hour following injection, and the somatotrophs fire in response, then return to baseline.

CJC-1295 with DAC produces sustained, relatively constant GHRH stimulation. Published human clinical trials with the DAC version showed sustained 2-3 fold elevations in GH and IGF-1 lasting weeks after a single injection. The clinical trials used once-weekly or once-every-two-weeks dosing.

Human Clinical Data

CJC-1295 with DAC was studied in Phase I and Phase II clinical trials that were published in the Journal of Clinical Endocrinology and Metabolism. These trials in healthy adults demonstrated dose-dependent increases in GH and IGF-1, excellent tolerability, and effects lasting over a week per injection. This represents a substantially stronger evidence base than most peptides in the longevity and performance community have — actual human pharmacokinetic and pharmacodynamic data.

The trials were conducted in the context of potential pharmaceutical development for growth hormone deficiency, but the research was discontinued before Phase III completion. The data nonetheless provides genuine human pharmacology information.

Stacking with GHRPs

CJC-1295 is almost universally stacked with a growth hormone releasing peptide (GHRP) — most commonly ipamorelin, GHRP-2, or GHRP-6. The rationale is that GHRH and GHRPs work through completely different receptor systems (GHRH receptor vs. ghrelin receptor) that act synergistically at the pituitary.

Animal studies demonstrate that combining a GHRH analog with a GHRP produces GH pulses approximately 10 times larger than either agent alone. The synergy is not additive but multiplicative — each pathway amplifies the effect of the other. This synergy is the primary reason combination protocols are universally preferred to monotherapy.

Dosing Protocols

CJC-1295 without DAC (Modified GRF 1-29): 100mcg subcutaneously 2-3 times daily, typically with ipamorelin 200-300mcg at the same time. Best timed before sleep (exploiting the natural nocturnal GH pulse) and morning.

CJC-1295 with DAC: 1-2mg subcutaneously once weekly. Some protocols use 2mg every two weeks. The extended half-life makes frequent dosing unnecessary.

FAQ

Q: Which form of CJC-1295 is better?

For mimicking physiological GH pulsatility, the non-DAC version dosed 2-3 times daily is preferred by many practitioners. The DAC version offers convenience (weekly dosing) and has actual human trial data supporting its pharmacological effects. The non-DAC version is often preferred when stacking with GHRPs for synergistic pulsatile release.

Q: What IGF-1 increase should be expected?

Human trials with DAC showed 1.5-3x IGF-1 elevations. The non-DAC version with twice-daily dosing in combination with a GHRP may produce similar or greater elevations depending on baseline values and individual response.

Q: Are there risks from chronically elevated IGF-1?

Epidemiological data shows associations between chronically high IGF-1 and some cancer risks. The relevance of pharmacologically elevated IGF-1 in this range is debated. IGF-1 within the upper physiological range is associated with muscle mass, bone density, and cognitive function benefits in aging. The balance of risks and benefits depends significantly on individual context.

Track your supplements in Optimize.